Circulating soluble CTLA-4 is related to inflammatory markers in the 70 year old population

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 70, Issue 4, 2010, Pages 237-243

  Sakthivel, Priya ^a   Wermeling, Fredrik ^a   Elmgren, Anders ^b   Hulthe, Johannes ^b   Kakoulidou, Maria ^a,c   Kari Lefvert, Ann ^a   Lind, Lars ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemokines; Pro inflammatory cytokines; Soluble CTLA 4; Vasculature and inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

AGED; ANALYSIS OF VARIANCE; ARTICLE; CAUCASIAN; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TURBIDIMETRY;

AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; RISK FACTORS;

EID: 77953863936     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365511003695608     Document Type: Article

References (35)

1. Tavora F [1] , Kutys R, Li L, Ripple M, Fowler D, Burke A. Adventitial lymphocytic infl ammation in human coronary arteries with intimal atherosclerosis. Cardiovasc Pathol 2009. In press.
2. Sattler A, Wagner U, Rossol M, Sieper J, Wu P, Krause A, Schmidt WA, Radmer S, Kohler S, Romagnani C, Thiel A. Cytokine-induced human IFN-gamma-secreting effectormemory Th cells in chronic autoimmune infl ammation. Blood 2009;113:1948-1956
3. Boulougouris G, McLeod JD, Patel YI, Ellwood CN, Walker LS, and Sansom DM. Positive and negative regulation of human T cell activation mediated by the CTLA-4/CD28 ligand CD80. J Immunol 1998;161:3919-3924
4. Krummel MF and Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-465
5. Hebbar M, Jeannin P, Magistrelli G, Hatron PY, Hachulla E, Devulder B, Bonnefoy JY, Delneste Y. Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis. Clin Exp Immunol 2004;136:388-392
6. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, and Tector AJ. A native soluble form of CTLA-4. Cell Immunol 2000;201:144-153
7. Wong CK, Lit LC, Tam LS, Li EK, and Lam CW. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44:989-994
8. Ip WK, Wong CK, Leung TF, and Lam CW. Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma . Int Arch Allergy Immunol 2005;137:45-52.
9. Sakthivel P, Shively V, Kakoulidou M, Pearce W, Lefvert AK. The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm. J Intern Med 2007;261:399-407.
10. Hock BD, Patton WN, Budhia S, Mannari D, Roberts P, and McKenzie JL. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukaemia patients. Leukemia 2002;16:865-873
11. Hock BD, Starling GC, Patton WN, Salm N, Bond K, McArthur LT, McKenzie JL. Identifi cation of a circulating soluble form of CD80: levels in patients with hematological malignancies. Leuk Lymphoma 2004;45:2111-2118
12. Oaks MK and Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 2000;164:5015-5018
13. Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang D, Pirskanen R, Lefvert AK. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J Neuroimmunol 2002;130: 224-232
14. Lind L, Fors N, Hall J, Marttala K and Stenborg A. A comparison of three different methods to evaluate endothelium- dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol 2005;25: 2368-2375
15. Kakoulidou M, Wang X, Zhao X, Pirskanen R, Lefvert AK. Soluble costimulatory factors sCD28, sCD80, sCD86 and sCD152 in relation to other markers of immune activation in patients with myasthenia gravis. J Neuroimmunol 2007; 185:150-161 .
16. Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005;51:1165-1176
17. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D ' Agostino RB; Framingham Heart Study. Infl ammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003;107:1486-1491 (Pubitemid 36378485)
18. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 2006;95:511-518
19. Hamer M, Chida Y. Associations of very high C-reactive protein concentration with psychosocial and cardiovascular risk factors in an ageing population. Atherosclerosis 2009; 206:599-603.
20. Wong CK, Szeto CC, Chan MH, Leung CB, Li PK, Lam CW. Elevation of pro-infl ammatory cytokines, C-reactive protein and cardiac troponin T in chronic renal failure patients on dialysis. Immunol Invest 2007;36:47-57.
21. Guven A, Cetinkaya A, Aral M, Sokmen G, Buyukbese MA, Guven A, Koksal N. High-sensitivity C-reactive protein in patients with metabolic syndrome. Angiology 2006;57: 295-302.
22. Ozeren A, Aydin M, Tokac M, Demircan N, Unalacak M, Gurel A, Yazici M. Levels of serum IL-1beta, IL-2, IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris. Mediators Infl amm 2003;12:361-365
23. Inoue T, Komoda H, Nonaka M, Kameda M, Uchida T, and Node K. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol 2007;124:319-325
24. Braunersreuther V, Mach F, Steffens S. The specifi c role of chemokines in atherosclerosis. Thromb Haemost 2007;97: 714-721
25. Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H, Haqqani AS, Kreymborg K, Krug S, Moumdjian R, Bouthillier A, Becher B, Arbour N, David S, Stanimirovic D, Prat A. Activated leukocyte cell adhesion molecules promotes leukocyte traffi cking into the central nervous system. Nat Immunol 2008;9:137-145
26. Turhan H, Erbay AR, Yasar AS, Aksoy Y, Bicer A, Yetkin G, Yetkin E. Plasma soluble adhesion molecules; intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin levels in patients with isolated coronary artery ectasia. Coron Artery Dis 2005;16:45-50.
27. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Infl ammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003;108:2317-2322
28. Kaaja RJ, Poyhonen-Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens 2006;24:131-141
29. Van Vré EA, Bult H, Hoymans VY, Van Tendeloo VF, Vrints CJ, Bosmans JM. Human C-reactive protein activates monocyte-derived dendritic cells and induces dendritic cellmediated T-cell activation. Arterioscler Thromb Vasc Biol 2008;28:511-518
30. Castoldi G, Galimberti S, Riva C, Papagna R, Querci F, Casati M, Zerbini G, Caccianiga G, Ferrarese C, Baldoni M, Valsecchi MG, Stella A. Association between serum values of C-reactive protein and cytokine production in whole blood of type 2 diabetic patients. Clin Sci (Lond) 2007;113:103-108
31. Papadopoulou C, Corrigall V, Taylor PR, Poston RN. The role of the chemokines MCP-1, GRO-alpha, IL-8 and their receptors in the adhesion of monocytic cells to human atherosclerotic plaques. Cytokine 2008;43:181-186
32. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, Delneste Y. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol 1999;29: 3596-3602
33. Sato S, Fujimoto M, Hasegawa M, Komura K, Yanaba K, Hayakawa I, Matsushita T, Takehara K. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 2004;43:1261-1266
34. Vandenborre K, Van Gool SW, Kasran A, Ceuppens JL, Boogaerts MA, Vandenberghe P. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation. Immunology 1999;98:413-421
35. Krabbe KS, Pedersen M, Bruunsgaard H. Infl ammatory mediators in the elderly. Exp Gerontol 2004;39:687-699